<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>9</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>09</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Immunotherapeutic Effects of Dendritic Cells Pulsed with a Coden-optimized HPV 16 E6 and E7 Fusion Gene in Vivo and in Vitro</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3843</FirstPage>
			<LastPage>3847</LastPage>
			<ELocationID EIdType="pii">30998</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; : Cervical cancer is the second most common cause of cancer related death of women. PersistentHPV infection, especially with high-risk types such as HPV16 and HPV18, has been identified to be the primarycause of cervical cancer. E6 and E7 are the major oncoproteins of high-risk HPVs, which are expressed exclusivelyin HPV infected tissues, and thereby represent ideal therapeutic targets for immunotherapy of cervical cancer.Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: In this work, we used recombinant adenovirus expressing coden-optimized HPV16 E6and E7 fusion protein (Ad-ofE6E7) to prime dendritic cells (DC-ofE6E7), to investigate the ability of primed DCvaccine in eliciting antitumor immunity in vitro and vivo. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Our results indicated that DC-ofE6E7 vaccineco-culturing with splenocytes could strongly induce a tumor-specific cytotoxic T lymphocyte (CTL) responseand kill the TC-1 cells effectively in vitro. Moreover, DC-ofE6E7 vaccine induced protective immunity againstthe challenge of TC-1 cancer cells in vivo. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: The results suggested that the HPV16 ofE6E7 primedDC vaccine has potential application for cervical cancer immunotherapy.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Human papillomavirus 16</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">E6</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">E7</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Dendritic Cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Vaccine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">cervical cancer</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30998_c22883d25d54ed1d6c9f213f34a19454.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
